Chronic respiratory disease, comorbid cardiovascular disease and mortality in a representative adult US cohort

Respirology

Volumn 18, Issue 7, 2013, Pages 1083-1088

  Mannino, David M ^a   Davis, Kourtney J ^c   Disantostefano, Rachael L ^b  

^a UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

cardiovascular disease; mortality; obstruction; restriction; spirometry

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC RESPIRATORY TRACT DISEASE; COMORBIDITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; UNITED STATES;

CARDIOVASCULAR DISEASE; MORTALITY; OBSTRUCTION; RESTRICTION; SPIROMETRY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; NUTRITION SURVEYS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84884868808     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12119     Document Type: Article

References (21)

1. Minino AM, Xu J, Kochanek KD,. Death in the United States, 2008. Natl Vital Stat. Rep. 2010; 59: 1-72.
2. Mannino DM, Buist AS,. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773.
3. Sin DD, Man SF, Marciniuk DD, et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulm. Med. 2006; 6: 3.
4. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD 2008; 5: 235-256.
5. Mannino DM, Doherty DE, Buist AS,. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir. Med. 2006; 100: 115-122.
6. Johnston AK, Mannino DM, Hagan GW, et al. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008; 63: 599-605.
7. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994; 309: 901-911.
8. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
9. D'Agostino RB, Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187.
10. Enright PL,. Smoking, lung function, and atherosclerosis in the 5,000 elderly participants of the Cardiovascular Health Study. Am. J. Geriatr. Cardiol. 1994; 3: 35-38.
11. Fimognari FL, Scarlata S, Antonelli-Inc. Why are people with 'poor lung function' at increased atherothrombotic risk?: a critical review with potential therapeutic indications. Curr. Vasc. Pharmacol. 2010; 8: 573-586.
12. Kalhan R, Tran BT, Colangelo LA, et al. Systemic inflammation in young adults is associated with abnormal lung function in middle age. PLoS ONE 2010; 5: e11431.
13. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am. J. Respir. Crit. Care Med. 1999; 159: 179-187.
14. Rodriguez-Roisin R, Anzueto A, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2011. [Accessed 30 May 2013.] Available from URL: http://www.goldcopd. org/uploads/users/files/GOLD2011-Summary.pdf
15. Barr RG, Ahmed FS, Carr JJ, et al. Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. Eur. Respir. J. 2012; 39: 846-854.
16. Lindberg A, Larsson LG, Ronmark E, et al. Co-morbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function. COPD 2011; 8: 421-428.
17. Fimognari FL, Pasqualetti P, Moro L, et al. The association between metabolic syndrome and restrictive ventilatory dysfunction in older persons. J. Gerontol. A Biol. Sci. Med. Sci. 2007; 62: 760-765.
18. Enright PL, Kronmal RA, Higgins MW, et al. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest 1994; 106: 827-834.
19. Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011; 66: 430-437.
20. Chaves PH, Kuller LH, O'Leary DH, et al. Subclinical cardiovascular disease in older adults: insights from the Cardiovascular Health Study. Am. J. Geriatr. Cardiol. 2004; 13: 137-151.
21. Mannino DM, Diaz-Guzman E,. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest 2012; 141: 73-80.